Risk Reduced Drug Development

SynDevRx™, Inc. develops polymeric pro-drugs for cancer based on our proprietary injectable drug release technology. Our technology provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile and increasing a drug's therapeutic index.

Our lead drug candidate inhibits an enzyme which independent research has shown to be central to tumor growth, proliferation and metastasis.

Our proprietary technology enhances that activity by specifically delivering and releasing the active drug moiety in the the target diseased tissue. Keeping the active drug sequestered and out of general circulation is seen as an effective way to greatly reduce off-target toxicities associated with small molecule drugs.